6293-01-2Relevant articles and documents
COMPOSITIONS AND METHODS FOR THE TREATMENT OF SEVERE PAIN
-
Paragraph 00104, (2013/12/03)
The invention relates to the compounds of formula (I) or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula (I), and methods for the treatment of severe pain may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of chronic pain, generalized pain disorders, leukemia, cancer, chronic pain, chemotherapy induced pain, epilepsy, migraine, neuropathic pain, post herpetic neuralgia, neuralgia, pain, drug addiction, detoxification of drugs, Alzheimer's disease, multiple sclerosis, multiple sclerosis restless legs syndrome (RLS), cluster headache, depression, fibromyalgia, amyotrophic lateral sclerosis (ALS), convulsions, partial seizures, mood-stabilizing agent and bipolar disorder.
Aminoalkyl substituted urea derivatives and method of treatment
-
, (2008/06/13)
The present invention relates to novel amino alkyl substituted urea derivatives as well as their acid addition salts with pharmaceutically acceptable acids, to methods for the preparation of said derivatives and pharmaceutical compositions containing same, and a method for the treatment of tumors therewith. The novel urea derivatives have shown pronounced anti-neoplastic activity when tested against various tumor models in animals. The novel compounds of the present invention may be represented by the following formula: STR1 wherein X and Y are the same or different and are selected from the group consisting of a phenyl group, each of said phenyl groups being optionally substituted with one or two groups selected from halogen, CF3, OH, or alkoxy (1-4 C-atoms); and R1 and R2 are the same or different, and are each selected from the group consisting of lower alkyl groups having from one to four carbon atoms inclusive, or they form together with the nitrogen atom a saturated five- or six-membered heterocyclic ring; R3 and R4 are each selected from hydrogen, lower alkyl or alkenyl groups with from 1-6 carbon atoms inclusive, cyclopentyl or cyclohexyl; and n is 0 or 1, as well as pharmaceutically acceptable acid addition salts thereof. When X is different from Y and/or R3 is different from R4 the compounds of Formula I exist as optical isomers, which may be separated in the individual enantiomers, which often show the activity in different degree. These individual isomers as well as their isolation fall within the scope of the present invention.
Dibenzo-18-crown-6 as phase transfer catalyst in Bockmuehl's synthesis of methadone
Poupaert, Jacques H.,Jeugd, Patrick van der,Gerardy, Bruno M.,Claesen, M.,Dumont, P.
, p. 2484 - 2492 (2007/10/02)
-
